BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS™ (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL.

Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the full procedure of a Left Atrial Appendage Occlusion (LAAO) for the first time in North America using a bio-realistic haptic simulator. This breakthrough was achieved by Dr. Reda Ibrahim (interventional cardiologist), Dr. Blandine Mondesert (electrophysiologist), and Dr. Walid Ben Ali (cardiac surgeon) utilizing a 3D-printed replica of the patient’s heart. This replica is part of a novel simulator that delivers realistic catheter navigation, haptic feedback, transesophageal echography, and fluoroscopic imaging.

“Rehearsing a specific case was very helpful—especially one in which we used innovative technologies like the new Abbott Steerable Delivery Sheath for the Amplatzer Amulet occluder, and the transseptal VersaCross Baylis System,” said Dr. Ibrahim. “This realistic simulation allowed us to maximize procedural success and safety.”

For this case, Biomodex printed a 3D patient-specific cardiac anatomy based on the patient’s own CTA images. Models are made of advanced materials that simulate the biomechanical characteristics and haptic feedback of the anatomy. Furthermore, the LAACS station replicates blood flow and viscosity and is ultrasound compatible. The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications.

Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease.

“Rehearsing these novel approaches using a patient-specific anatomical model is intended to better prepare physicians and potentially improve patient outcomes,” said Ziad Rouag, President and Chief Executive Officer of Biomodex. “It was an honor to support Dr. Ibrahim and his team.”

The rehearsal and subsequent live patient procedure were performed and recorded at the Montreal Heart Institute. Dr. Ibrahim and his team will present their live case at TVT 2021: The Structural Heart Summit on July 22 from 9:30am to 10:10am EDT (LAA Live Case #20: Update of Left Atrial Appendage Occlusion). To register, visit here.

SourceBIOMODEX
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy